Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis

Por Crowley, J.J., Warren, R.B., Cather, J.C.
Publicado no J Eur Acad Dermatol Venereol (2019)

Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

Por Wan, M. T., Alvarez, J., Shin, D. B., Dommasch, E. D., Wu, J. J., Gelfand, J. M.
Publicado no J Eur Acad Dermatol Venereol (2018)

Real‐life effectiveness of once‐daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52‐week PRO‐long study...

Por Lambert, J., Hol, C.W., Vink, J.
Publicado no J Eur Acad Dermatol Venereol (2015)

COVID‐19 and its implications for Dermatology and Venereology

Por Ring, J.
Publicado no J Eur Acad Dermatol Venereol (2020)

The skin in the era of coronavirus pandemic

Por Ring, J.
Publicado no J Eur Acad Dermatol Venereol (2020)

Dermato‐venereology in the year of coronavirus – Hot topics in research and patient care

Por Ring, J.
Publicado no J Eur Acad Dermatol Venereol (2021)

Impact of the COVID‐19 pandemic on inpatient dermatology: a multicentre study from Hubei, China

Por Zhang, Y., Wen, J., Alamgir, M., Xie, J., Jing, H., Fang, M., Wang, J., Zhang, M., Meng, Z., Yang, L., Tao, J.
Publicado no J Eur Acad Dermatol Venereol (2020)

Autoantibodies in Covid‐19 – a model for viral induced autoimmunity

Por Berger, J., Volc, S.
Publicado no J Eur Acad Dermatol Venereol (2021)

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

Por Kimball, A.B., Crowley, J.J., Papp, K., Calimlim, B., Duan, Y., Fleischer, A.B., Sobell, J.
Publicado no J Eur Acad Dermatol Venereol (2020)

Acro‐ischaemia and COVID‐19 infection: clinical and histopathological features

Por Calvão, J., Relvas, M., Pinho, A., Brinca, A., Cardoso, J.C.
Publicado no J Eur Acad Dermatol Venereol (2020)

Penile ischaemia secondary to COVID‐19: why should the dermatologist be concerned?

Por Sarkis, P., Sarkis, J., Alkassis, M., Assaf, J., El Gharib, K.
Publicado no J Eur Acad Dermatol Venereol (2021)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from...

Por Mease, P.J., Palmer, J.B., Hur, P., Strober, B.E., Lebwohl, M., Karki, C., Reed, G.W., Etzel, C.J., Greenberg, J.D., Helliwell, P. S.
Publicado no J Eur Acad Dermatol Venereol (2019)

Efficacy of hydrogel patches in preventing facial skin damage caused by mask compression in fighting against coronavirus disease 2019: a short‐term, self‐controlled study

Por Dong, L., Yang, L., Li, Y., Yang, J., An, X., Yang, L., Zhou, N., Zhang, Y., Du, H., Lan, J., Song, Z., Miao, X., Zhu, J., Tao, J.
Publicado no J Eur Acad Dermatol Venereol (2020)

Measurement of Tanning Dependence

Por Heckman, C.J., Darlow, S., Kloss, J.D., Cohen-Filipic, J., Manne, S.L., Munshi, T., Yaroch, A.L., Perlis, C.
Publicado em 2013

Incidence and prognosis of COVID‐19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study

Por Georgakopoulos, J.R., Mufti, A., Vender, R., Prajapati, V.H., Yeung, J.
Publicado no J Eur Acad Dermatol Venereol (2021)

Occupational skin disease during the COVID‐19 pandemic, as captured in a Dermatology staff clinic in the United Kingdom

Por Hadjieconomou, S., Hughes, J., Kamath, S.
Publicado no J Eur Acad Dermatol Venereol (2020)

Concerns and perceptions of patients with psoriatic disease during the COVID‐19 pandemic: results from a two‐wave survey by the National Psoriasis Foundation

Por Gondo, G.C., Bell, S.J., Slayden, J., Ullmann, G., Blauvelt, A.
Publicado no J Eur Acad Dermatol Venereol (2021)

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis

Por Merola, J.F., Ghislain, P.‐D., Dauendorffer, J.N., Potts Bleakman, A., Brnabic, A.J.M., Burge, R., Riedl, E.
Publicado no J Eur Acad Dermatol Venereol (2020)

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a...

Por van Vugt, L.J., van den Reek, J.M.P.A., Meulewaeter, E., Hakobjan, M., Heddes, N., Traks, T., Kingo, K., Galluzzo, M., Talamonti, M., Lambert, J., Coenen, M.J.H., de Jong, E.M.G.J.
Publicado no J Eur Acad Dermatol Venereol (2019)

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from t...

Por Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Publicado no J Eur Acad Dermatol Venereol (2018)